Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THE-0504 in Solid Tumors
NCT07646106Phase 1Recruiting
- Sponsor
- Thena Biotech
- Start
- Nov 2024
- Primary completion
- May 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of The-0504 in solid tumor, sponsored by Thena Biotech. Primary endpoints: Maximum Tolerated Dose at 3 weeks and Recommended Phase 2 Dose at 3 weeks. Started Nov 2024; status: recruiting.
02
Drugs
The-0504
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07646106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07646106.